Nonsense Tx develops small-molecule therapies to increase collagen 7 production, specifically targeting nonsense mutations in Dystrophic Epidermolysis Bullosa (DEB) patients. This approach aims to mitigate the severe disease outcomes associated with these genetic mutations.
Funding
Funding not disclosed
Founders
Product
Problem
Nonsense mutations, which cause premature termination codons, account for 10-12% of rare disease cases, often leading to the most severe disease outcomes due to incomplete protein translation. In Recessive Dystrophic Epidermolysis Bullosa (RDEB), these mutations in the COL7A1 gene result in truncated, non-functional collagen 7, leading to fragile skin and blistering. Currently, there is no cure for RDEB, and treatments primarily focus on managing symptoms.
Solution
Nonsense Tx is developing small-molecule therapies designed to address nonsense mutations by promoting ribosome readthrough of premature termination codons. Their lead program, NTX-001, aims to restore the production of full-length, functional collagen 7 in patients with RDEB. By enabling the translation of complete proteins, Nonsense Tx's approach seeks to mitigate the underlying cause of the disease, potentially improving skin integrity and reducing the severity of blistering and other complications associated with RDEB. The company is also exploring applications of its technology to address other genetic diseases caused by nonsense mutations.
Target Audience
The primary target audience includes patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other individuals affected by genetic diseases caused by nonsense mutations.
Features
- NTX-001: A small molecule designed to promote ribosomal readthrough of premature termination codons (PTCs).
- Focus on restoring full-length, functional collagen 7 production in RDEB patients.
- Potential application to other genetic diseases caused by nonsense mutations.